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hydrochlorothiazide. Using the ACCOMPLISH results for valsartan/amlodipine, it is 
likely to have reasonably low costs per event avoided for the treatment of high risk 
patients with hypertension in Sweden.
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OBJECTIVES: Cytochrome P450 2C19 (CYP2C19) genotype has been shown to 
affect cardiovascular (CV) outcomes for clopidogrel but not prasugrel. This study 
evaluates the incremental cost-effectiveness ratio (ICER) of CYP2C19-guided vs. 
routine antiplatelet therapy in acute coronary syndrome (ACS) patients in the UK. 
METHODS: We constructed a literature-based, decision analytic, Markov model to 
estimate the annual cost-effectiveness of CYP2C19-guided aspirin plus either clopido-
grel or prasugrel therapy vs. no genotyping. Post-initial ACS CV events were based 
on the TRITON-TIMI 38 study and genetic substudy. Cost data sources were: 
National Health Service (NHS) reference cost for 2008–09—nonfatal MI and stroke, 
CV death, intracranial hemorrhage, other life-threatening bleed, and minor bleed; 
Drug Tariff 2009—drugs; www.genetic-health.co.uk/—CYP2C19 genotyping; or US-
based reference pricing converted to £ using appropriate exchange rates -monthly CV 
disease maintenance cost. Disease-state utilities were obtained from published sources. 
The model allowed for clopidogrel/prasugrel discontinuation and aspirin monother-
apy. Model sensitivity was assessed using 1-way analysis of parameters varied by 
quartile or at least +/− 25%. RESULTS: The analysis demonstrated an increase in 
incremental cost (£81); greater incremental QALY (0.05); and an ICER £1529/QALY 
for CYP2C19 genotype-guided therapy over 12 months. The model was most sensitive 
to monthly CV care cost, NFMI cost, proportion of patients on clopidogrel, and life-
threatening bleeding cost. The model was least sensitive to the cost of clopidogrel, 
prasugrel, or CYP2C19 genotyping. CONCLUSIONS: The model-based ICER of 
£1,529/QALY for the CYP2C19 testing strategy is signiﬁ cantly less than the UK 
threshold of £20,000 that is considered good value. CYP2C19 genotype-guided clopi-
dogrel or prasugrel therapy is cost-effective for up to 1 year in ACS patients in the 
UK.
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OBJECTIVES: Dronedarone is a novel anti-arrhythmic drug (AAD) that, unlike other 
AADs, was shown to reduce cardiovascular hospitalizations or death in the ATHENA 
clinical trial. In addition, dronedarone reduces AF recurrence, maintains rate control, 
and has a favorable safety proﬁ le with low pro-arrhythmic and organ-toxicity proﬁ le. 
The objective of this study was to construct a health economic model to assess the 
cost-effectiveness of dronedarone vs. other AADs in a Canadian setting. METHODS: 
A state transition model evaluated through patient-level simulation has been developed 
using Microsoft Excel. It allows comparisons over varying time horizons and treat-
ment durations, and consists of health states for: treatment, off treatment, symptom-
atic AF recurrences, stroke, acute coronary syndromes, coronary heart failure and 
death. Transition probabilities were derived from the patient level data from the 
ATHENA trial, and relative risks between dronedarone and three commonly used 
comparators (amiodarone, sotalol and ﬂ ecainide) identiﬁ ed by clinical experts were 
derived from a mixed treatment comparison (systematic review) of published clinical 
trials published between 1980 and 2009. Patients discontinuing treatments were 
assumed to progress according to the rates in the standard of care arm of ATHENA. 
Costs of monitoring and initiation were taken into account. Costs were applied to 
each adverse event (AE) observed (Canadian Costs [C$] 2007). Effectiveness was 
expressed as QALYs, using preference based utility weights for health states based on 
published data. Discounting was 5% and a lifetime horizon was taken. RESULTS: 
The model predicts higher quality adjusted survival for patients on dronedarone: 
between 1.13 and 2.01 QALYs depending on comparator. In Canada, the resulting 
ICERs (per QALY) are C$5600 compared to amiodarone, C$5300 compared to ﬂ e-
cainide, and C$5300 compared to sotalol. Results were sensitive to differences in risk 
of mortality between treatment groups. CONCLUSIONS: Dronedarone represents a 
cost-effective treatment for patients with atrial ﬁ brillation in Canada.
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OBJECTIVES: To perform a cost-effectiveness analysis (CEA) for the use of droneda-
rone in patients with atrial ﬁ brillation (AF) in order to prevent hospitalizations due 
to cardiovascular events or death (HCED), from the public health care system perspec-
tive in Mexico. METHODS: A CEA was made based on the clinical information from 
the multicenter, randomized, clinical study ATHENA, where dronedarone was com-
pared to placebo on top of standard treatment in patients with AF. Overall, 2301 
patients were randomized to dronedarone, and 2327 to placebo. The primary clinical 
endpoint was HCED. Only direct medical health care costs were calculated. The health 
resource utilization was elicited from the ATHENA trial. The unit costs of each event 
were obtained from the medical literature and/or validated by local experts, whenever 
information was not available. Most of the cost information is based on IMSS (Social 
Security) ﬁ gures, and updated to year 2009 (1c = MX$17.05). a discount rate of 5% 
was used. An incremental cost-effectiveness analysis was performed complemented by 
a deterministic sensitivity analysis (DSA) to assess robustness of the model. RESULTS: 
Patients randomized to dronedarone experienced 1190 events of HCED (average rate 
0.51 [CI 95%: 0.47–0.55]) while patients in the placebo group had 1601 (average 
rate 0.69 [CI 95%: 0.64–0.74]), or −415 events, 18% less hospitalizations (CI 95%: 
12–25%) for the dronedarone group. The average cost per patient in the dronedarone 
group was c3028 as compared to the placebo group of c2,941, yielding a cost differ-
ence of c87.4, and an avoided incremental cost per HCED of c477.00 of dronedarone 
vs. the placebo group. The DSA shows the analysis is robust. CONCLUSIONS: 
According to the ATHENA trial, dronedarone is a cost-effective treatment option for 
the reduction of HCED from the Mexican perspective. Dronedarone’s value could be 
enhanced if indirect costs averted from the decreased rates of HCED included.
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OBJECTIVES: The aim of this study is to estimate cost-effectiveness of lowering low-
density lipoprotein cholesterol (LDL-C) with statin monotherapy in patients with 
elevated LDL-C with two or more cardiovascular risk factors or either coronary heart 
disease (CHD) in Spain. METHODS: A Markov model was developed to represent 
the transition of a cohort of patients with elevated LDL-C or with CHD at risk of a 
cardiovascular event (CVE) through four health states: patients with LDL-C, CVE, 
death by CVE and death by other causes. Probabilities of a CVE in females and males 
were determined, based on CHD risks estimated trough locally-adjusted Framingham 
risk equations using data from the DORICA and PRIMULA study. LDL-C lowering 
efﬁ cacy of statins, mortality, and health-state utilities were obtained from published 
scientiﬁ c literature. Cardiovascular risk factors included were age, systolic blood pres-
sure, diabetes, smoking and high-density lipoprotein cholesterol (HDL-C). Treatment 
and CVE direct medical costs were obtained from a medication database and DRGs 
for public hospitals in 2009 in Spain. Deterministic results were estimated and a 
probabilistic sensitivity analysis was conducted. Results were expressed as expected 
cost per quality adjusted life-years (QALYs) gained. RESULTS: In deterministic analy-
ses, expected costs per patient per year at age of 40 were higher for patients with 2 
or more cardiovascular risk factors who were not treated than those who were treated 
(female: c41,300 vs. c40,106; male: c22,160 vs. c18,333). Effectiveness was higher 
for treated patients in both genders (female: 0.17 QALY; male: 0.37 QALY). Similar 
results were found for patients with CHD (female: c35,706 vs. c34,664, 0.10 QALY; 
male: c16,892 vs. c16,073, 0.12 QALY). CONCLUSIONS: From the perspective of 
the Spanish health care system, treatment with statin monotherapy is considered to 
be cost-effective versus no treatment in female and male patients with 2 or more risk 
factors or CHD.
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OBJECTIVES: High resting heart rate (HR) has been progressively accepted as a 
modiﬁ able cardiovascular risk factor. Ivabradine (ProcoralanÒ) is a speciﬁ c HR lower-
ing agent. This study aimed estimating the cost-effectiveness of ivabradine in stable 
angina patients with a normal sinus rhythm and a resting HR above 70 beats per 
minute (bpm) from the Austrian health care perspective: 1) versus generic diltiazem 
when beta-blockers (BB) are contra-indicated or non tolerated; and 2) in combination 
with generic atenolol versus generic atenolol alone. METHODS: A Markov chain 
Monte Carlo stochastic simulation model was used to estimate the inﬂ uence of HR 
lowering in cardiovascular morbidity and mortality and its economic consequences. 
Treatments considered are ivabradine, 7.5 mg twice a day, diltiazem, 240 mg once a 
day and atenolol 50 mg once a day. HR distribution, survival and time to hospitaliza-
tion were modelled as weibull functions. Events considered were acute myocardial 
infarction, stroke, heart failure, death and revascularization procedures. Only direct 
medical costs were included. Effectiveness was measured in quality-adjusted life-years 
(QALYs). Time horizon was set at 20 years and discount rates for costs and effective-
ness were 3%/year. RESULTS: The between-group difference in HR reduction was 
−6.4 bpm and −8.8 bpm in favour of ivabradine strategy in targeted patient popula-
tions 1) and 2) respectively. Incremental ivabradine strategy cost was c6789 versus 
generic diltiazem and c6749 versus generic atenolol. Incremental QALYs were 1.067 
and 1.076 respectively. Incremental cost-effectiveness ratios for ivabradine strategy 
were c5800/QALY and c6273/QALY. Deterministic sensitivity analyses showed that 
